CURR CANCER DRUG TAR

Publications

  1. 2020
  2. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL

    Nilsson, S., Stein, A., Rolfo, C., Kranich, A., Mann, J., Papadimitriou, K., Theile, S., Amberg, S. & Bokemeyer, C., 27.06.2020, In: CURR CANCER DRUG TAR. 20, 10, p. 811-817 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  3. 2017
  4. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma

    Atanackovic, D., Luetkens, T., Radhakrishnan, S. & Kroger, N., 2017, In: CURR CANCER DRUG TAR. 17, 9, p. 839-845 7 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  5. 2011
  6. Clinical experience with antiangiogenic therapy in leukemia.

    Wellbrock, J. & Fiedler, W., 2011, In: CURR CANCER DRUG TAR. 11, 9, p. 1053-1068 9.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  7. 2010
  8. Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?

    Staufer, K. & Stöltzing, O., 2010, In: CURR CANCER DRUG TAR. 10, 8, p. 890-897 8.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  9. 2008
  10. Allelic imbalances of the egfr gene as key events in breast cancer progression--the concept of committed progenitor cells.

    Agelopoulos, K., Buerger, H. & Brandt, B., 2008, In: CURR CANCER DRUG TAR. 8, 5, p. 431-445 5.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

  11. 2006
  12. Integrins in cancer treatment

    Eble, J. A. & Haier, J., 03.2006, In: CURR CANCER DRUG TAR. 6, 2, p. 89-105 17 p.

    Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review